Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment. + A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC
Phase 3RecruitingDevelopment Stage
Metabolic Syndrome
Metabolic Syndrome, Cardiovascular Disease (CKD), Cerebrovascular Disease, Qi Deficiency and Blood Stasis
Apr 24, 2025 → Jul 31, 2028
About Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment. + A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC
Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment. + A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC is a phase 3 stage product being developed by Brain Biotech for Metabolic Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06908473. Target conditions include Metabolic Syndrome, Cardiovascular Disease (CKD), Cerebrovascular Disease.
What happened to similar drugs?
19 of 20 similar drugs in Metabolic Syndrome were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06908473 | Phase 3 | Recruiting |
Competing Products
20 competing products in Metabolic Syndrome